Locations:
Search
Phase 1 trial shows up to 97% decrease through 48 weeks with good tolerability
Post hoc ALPACA analysis boosts biological rationale for ongoing outcomes trial of lepodisiran
Durability findings propel potential one-time treatment approach to phase 1b testing
Findings promise to shape future antiplatelet drug development and treatment strategies
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Robust signal from observational study raises prospect of a long-sought medical therapy
LLM-driven system uses both structured and unstructured data, provides auditable justifications
CD36 loss-of-function variant accounts for large portion of risk in this population
First-in-human phase 1 trial induced loss of function in gene that codes for ANGPTL3
Blood test can identify patients who need more frequent monitoring or earlier surgery to prevent dissection or rupture
Phase 3 TANDEM study may help pave way to first approval of a CETP inhibitor
Advertisement
Advertisement